JPMorgan Chase & Co. Has $555.80 Million Holdings in IDEXX Laboratories, Inc. $IDXX

JPMorgan Chase & Co. increased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 60.0% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 869,930 shares of the company’s stock after buying an additional 326,348 shares during the period. JPMorgan Chase & Co.’s holdings in IDEXX Laboratories were worth $555,802,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of the company. Blalock Williams LLC purchased a new stake in shares of IDEXX Laboratories in the third quarter valued at about $590,000. New York State Common Retirement Fund increased its stake in IDEXX Laboratories by 6.8% in the 3rd quarter. New York State Common Retirement Fund now owns 60,225 shares of the company’s stock valued at $38,477,000 after buying an additional 3,820 shares during the last quarter. Arkadios Wealth Advisors bought a new position in shares of IDEXX Laboratories during the 2nd quarter worth approximately $405,000. Mediolanum International Funds Ltd boosted its stake in shares of IDEXX Laboratories by 14.5% in the 3rd quarter. Mediolanum International Funds Ltd now owns 38,761 shares of the company’s stock worth $24,441,000 after buying an additional 4,909 shares during the last quarter. Finally, Principal Financial Group Inc. increased its position in shares of IDEXX Laboratories by 16.7% during the third quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company’s stock valued at $840,638,000 after acquiring an additional 187,967 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Jefferies Financial Group reiterated a “buy” rating and set a $830.00 price target on shares of IDEXX Laboratories in a report on Tuesday, November 4th. Stifel Nicolaus set a $775.00 price objective on shares of IDEXX Laboratories in a report on Monday, November 3rd. Weiss Ratings lowered shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. BTIG Research lowered their target price on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research note on Tuesday, February 3rd. Finally, Leerink Partners set a $785.00 target price on shares of IDEXX Laboratories in a research report on Monday, November 3rd. Seven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $783.33.

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP George Fennell sold 11,345 shares of IDEXX Laboratories stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the transaction, the executive vice president directly owned 9,823 shares of the company’s stock, valued at $6,352,730.56. The trade was a 53.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.98% of the stock is currently owned by insiders.

IDEXX Laboratories Stock Up 1.4%

IDXX opened at $634.90 on Thursday. The firm’s 50 day simple moving average is $680.64 and its two-hundred day simple moving average is $669.42. The company has a market capitalization of $50.70 billion, a PE ratio of 48.58, a PEG ratio of 3.81 and a beta of 1.67. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $769.98. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing the consensus estimate of $2.93 by ($0.01). The company had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter last year, the company earned $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, equities analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.